OakChart

Crescent Biopharma Inc

CBIOHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

14.76+0.84 (6.00%)
2026-11-12 05:38 CET
Market cap
548.06 USD m
Revenue, TTM
11.88 USD m
Net income, TTM
-165.12 USD m
Free cash flow, TTM
-73.60 USD m
EPS diluted, TTM
-7.65
P/E
-
Compare

Price

CBIO against its 20, 50 and 200-day averages
2050200beat
12.5015.0017.5020.0022.501.6M3.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CBIOclose 14.7620-day 13.2350-day 15.01200-day 15.9114.76

46.2% under the 52-week high of 27.41 on 22 Apr 2026. 52-week low 8.72 on 9 Feb 2026. Last 15 sessions, 20.0% high to low

Volume 0.79× normal · the line is the 50-bar volume average

Profile

CBIO
52-week range, 32% of the way up
8.7227.41

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

IndexRUT
Employees44
IPOJan 10, 2014
Beta1.36
ATR, 14d1.07
Rel volume0.79
Short float13.46%
Insider own16.78%
Inst own79.31%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap548.05M
Enterprise Value381.90M
Income-165.12M
Sales11.88M
Book/sh5.74
Cash/sh4.62
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees44
IPOJan 10, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S46.13
P/B2.57
P/C3.19
P/FCF-
EV/EBITDA-
EV/Sales32.15
Quick Ratio9.66
Current Ratio9.66
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-7.65
EPS next Y-3.19
EPS next Q-0.70
EPS this Y78.00%
EPS next Y-13.31%
EPS next 5Y37.23%
EPS past 3/5Y45.01% 33.26%
Sales past 3/5Y424.86% 1.31%
EPS Y/Y TTM78.59%
Sales Y/Y TTM-100.00%
EPS Q/Q85.60%
Sales Q/Q-
EarningsJul 30 BMO
EPS/Sales Surpr.-0.58% -100.00%

Ownership

Insider Own16.78%
Insider Trans14.07%
Inst Own79.31%
Inst Trans10.29%
ROA-97.08%
ROE-109.17%
ROIC-100.55%
Gross Margin98.22%
Oper. Margin-1417.74%
Profit Margin-1389.58%
SMA2011.55%
SMA50-1.71%
SMA200-7.28%
Trades-

Technical

Shs Outstand37.14M
Shs Float30.91M
Short Float13.46%
Short Ratio12.20
Short Interest4.16M
52W High27.41 -46.17%
52W Low8.72 69.21%
Volatility8.01% 7.72%
ATR (14)1.07
RSI (14)57.53
Beta1.36
Rel Volume0.79
Avg Volume341.19K
Volume269,425

Performance

Perf Week6.77%
Perf Month14.29%
Perf Quarter-11.27%
Perf Half Y-24.76%
Perf YTD24.41%
Perf Year11.36%
Perf 3Y-87.70%
Perf 5Y-92.73%
Perf 10Y-97.78%
Recom1.00
Target Price31.50
Prev Close13.92
Price14.76
Change %6.00%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 06, 2026UpgradeHH.C. WainwrightNeutral → Buy$36+144.0%
Jun 01, 2026DowngradeHH.C. WainwrightBuy → Neutral
Jan 28, 2026InitiatedPPiper SandlerOverweight$35+137.2%
Jan 21, 2026InitiatedGGuggenheimBuy$35+137.2%
Aug 25, 2025InitiatedJJefferiesBuy$26+76.2%
Aug 11, 2025InitiatedHH.C. WainwrightBuy$25+69.4%
Jul 14, 2025InitiatedWWedbushOutperform$27+83.0%
Jun 25, 2025InitiatedSStifelBuy$28+89.8%
Mar 21, 2025InitiatedCCantor FitzgeraldOverweight
Jul 26, 2024DowngradeTTD CowenBuy → Hold

Peers

Mkt cap
TickerCompanyMkt cap
SMMTSummit Therapeutics Inc13.27B
BCAXBicara Therapeutics Inc699.06M
BNTXBioNTech SE ADR21.73B
MGNXMacrogenics Inc147.78M
ZYMEZymeworks BC Inc2.02B
STROSutro Biopharma Inc170.12M
CTMXCytomX Therapeutics Inc464.35M
PYXSPyxis Oncology Inc196.16M
WHWKWhitehawk Therapeutics Inc191.19M
XLOXilio Therapeutics Inc55.74M

Insider trading

latest 14 of 22
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Lynch RyanSee RemarksSep 16 '26Sale17.902404,29613,631Sep 18 04:03 PM
Pinkas JanChief Scientific OfficerSep 16 '26Sale17.9065811,77821,581Sep 18 04:03 PM
Im Ellie EunkyungChief Medical OfficerSep 16 '26Sale17.9062311,15221,446Sep 18 04:02 PM
Scalzo Richard WilliamChief Financial OfficerSep 16 '26Sale17.9056810,16719,730Sep 18 04:02 PM
Bispham Barbara HarlinSee RemarksSep 16 '26Sale17.9062011,09818,710Sep 18 04:02 PM
Brumm Joshua TChief Executive OfficerSep 18 '26Sale16.717,837130,956271,765Sep 18 04:02 PM
Brumm Joshua TChief Executive OfficerSep 16 '26Sale17.901,61028,819279,602Sep 18 04:02 PM
McNeill JonathanPresident and COOSep 18 '26Sale16.713,83964,150134,588Sep 18 04:01 PM
McNeill JonathanPresident and COOSep 16 '26Sale17.9073113,085138,427Sep 18 04:01 PM
Joshua T BrummOfficerSep 18 '26Proposed Sale17.189,013154,843Sep 17 04:33 PM
Jonathan McNeillOfficerSep 18 '26Proposed Sale17.184,41575,850Sep 17 04:32 PM
Jonathan McNeillOfficerSep 16 '26Proposed Sale18.8080415,115Sep 16 03:09 PM
Joshua T BrummOfficerSep 16 '26Proposed Sale18.801,77133,295Sep 16 03:09 PM
Fairmount Funds Management LLCDirectorJul 16 '26Buy14.50853,45012,375,0253,601,316Jul 20 05:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
VHTVanguard Health Care ETFAUM: 21.51B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
RSSLGlobal X Russell 2000 ETFAUM: 1.43B

News

latest 14 of 198
  • Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire) +5.82%
  • Crescent Biopharma to Present at November Investor Conferences (GlobeNewswire)
  • Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
  • Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors (GlobeNewswire)
  • Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
  • Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
  • Crescent Biopharma to Present at September Investor Conferences (GlobeNewswire) +10.03%
  • Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire)
  • Crescent Biopharma: Q2 Earnings Snapshot (Associated Press)
  • Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
  • Crescent Biopharma Announces Grants of Inducement Awards (GlobeNewswire) +7.58%
  • Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
  • Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)
  • Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-07-30-0.740-0.736-0.7400.000.367
2026Q12026-04-29-0.700-0.879-0.7661.000.367
2025Q42026-02-26-4.010-2.472-4.58110.8410.008
2025Q32025-11-06-1.270-1.959-1.4880.000.006
2025Q22025-07-31-4.930-1.667-5.6500.000.004
2025Q12025-05-01-6.988-5.000-3.6320.000.001
2024Q42025-02-27-8.000--11.2010.00--
2024Q22024-08-01-15.000-16.750-15.6560.000.004
2024Q12024-05-10-17.000-16.000-16.6570.000.004
2023Q42024-03-27-14.000-15.250-14.0990.010.004
2023Q32023-11-03-14.000-14.330-14.3010.000.003
2023Q22023-08-02-13.000-18.330-12.8490.000.053
2023Q12023-05-03-17.000-16.670-17.1650.000.003
2022Q42023-03-29-19.000-21.330-19.3440.000.003
2022Q32022-11-09-16.000-25.000-16.2590.000.003
2022Q22022-08-03-25.000-28.500-25.3160.080.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-134-128.67-133.840.000.00
2020FY-112-108.2-111.6110.1610.00
2021FY-123-124.75-123.271.160.84
2022FY-89.000-87.000-88.8780.080.07
2023FY-58.000-60.250-58.2540.010.00
2024FY-59.000--23.2770.00-
2025FY-12.810-10.260-12.81010.847.50
2026FY--2.818--2.15
2027FY--3.193--2.50
2028FY--3.168--5.00
2029FY--2.969--30.00
2030FY--2.509--160

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-074000.630.002.50
2026Q3S2026-07-307000.360.002.50
2026Q3S2026-04-307000.360.002.50
2026Q3S2026-02-267000.360.002.50
2026Q3S2026-01-274000.000.000.00
2026Q3S2026-01-203000.000.000.00
2026Q3S2025-12-032000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-052000.000.000.00

Estimate history

EPS, annual-113-117.613-133.839-111.605-123.272-88.878-58.254-23.277-14.783-7.6478
Period201720182019202020212022202320242025TTM
EPS, quarterly-15.656-15.235-11.201-3.632-5.65-1.488-4.581-0.766-0.814
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00010.1631.160.0750.01010.84411.88
Period201720182019202020212022202320242025TTM
Sales, quarterly00000010.8441.0390
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.3440.4320.4350.490.5230.5440.6441.01927.55727.756
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.6450.6450.6450.64513.89313.89327.55727.57227.756
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue11.8810.840.000.010.071.1610.160.000.00
Cost of Goods Sold Incl. D&A0.210.080.000.151.031.010.950.900.28
Gross Profit11.6710.760.00-0.14-0.960.159.21-0.90-0.28
Selling, General and Administrative Excl. Other181.91163.3917.1939.1346.4563.5960.7260.4951.23
Research and Development152.67138.0914.0320.0728.3947.4944.9347.0340.09
Other Operating Expense-1.770.000.000.000.000.000.000.000.00
Operating Income-168.47-152.63-17.19-39.28-47.40-63.45-51.51-61.39-51.50
Interest Expense-2.190.850.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00-
Net Income Before Taxes-163.12-151.94-17.87-36.90-46.69-63.43-51.03-57.89-48.27
Income Taxes2.002.000.000.000.000.000.000.000.00
Consolidated Net Income-165.12-153.94-17.87-36.90-46.69-63.43-51.03-57.89-48.27
Net Income From Continuing Operations-165.12-153.94-17.87-36.90-46.69-63.43-51.03-57.89-48.27
Net Income-165.12-153.94-17.87-36.90-46.69-63.43-51.03-57.89-48.27
EPS (Recurring)-5.41-14.78-23.28-58.25-88.88-123.27-111.60-133.84-117.61
EPS (Basic, Before Extraordinaries)-7.65-14.78-23.28-58.25-88.88-123.27-111.61-133.84-117.61
EPS (Diluted)-7.65-14.78-23.28-58.25-88.88-123.27-111.61-133.84-117.61
EBITDA-168.26-152.55-17.19-39.12-46.37-62.43-50.56-60.49-51.23
Non-Operating Income (Expense)5.352.880.182.380.710.020.483.503.23
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense12.9510.511.133.523.866.096.906.224.59
Price To Sales Ratio46.2511.39-14,948.822,122.2663.8916.92--
Gross Margin98.2299.23--1,433.01-1,276.2112.6090.64--
Operating Margin-1,417.74-1,407.52--392,752.93-63,204.43-5,470.69-506.84--
Net Margin-1,389.58-1,419.61--368,994.20-62,251.74-5,468.98-502.09--
Shares Outstanding27.7627.561.020.640.540.520.490.430.43
Market Capitalization548.06548.0616.06151.91158.8475.33184.31229.94408.73

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.001.0410.840.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.070.060.050.030.000.000.000.01
Gross Profit-0.070.9710.79-0.03-0.000.000.00-0.01
Selling, General and Administrative Excl. Other28.0725.70102.2825.8621.032.405.325.71
Research and Development19.3917.9095.0320.3512.080.010.231.72
Other Operating Expense-1.770.000.000.000.000.000.000.00
Operating Income-26.36-24.73-91.49-25.89-21.03-2.40-5.32-5.72
Interest Expense0.000.000.00-1.070.000.000.00
Unusual Expense0.000.000.000.000.000.002.025.51
Net Income Before Taxes-24.84-23.28-90.40-24.61-21.79-2.34-7.22-9.82
Income Taxes0.000.002.000.000.000.000.000.00
Consolidated Net Income-24.84-23.28-92.40-24.61-21.79-2.34-7.22-9.82
Net Income From Continuing Operations-24.84-23.28-92.40-24.61-21.79-2.34-7.22-9.82
Net Income-24.84-23.28-92.40-24.61-21.79-2.34-7.22-9.82
EPS (Recurring)-0.81-0.77-4.58-1.49-5.65-3.63-9.01-9.25
EPS (Basic, Before Extraordinaries)-0.81-0.77-4.58-1.49-5.65-3.63-11.20-15.23
EPS (Diluted)-0.81-0.77-4.58-1.49-5.65-3.63-11.20-15.23
EBITDA-26.30-24.66-91.44-25.86-21.03-2.40-5.32-5.71
Non-Operating Income (Expense)1.531.451.091.280.310.060.111.41
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.963.253.751.995.340.411.161.14
Price To Sales Ratio46.2546.9922.06----1,089.78
Gross Margin-93.8499.50-----
Operating Margin--2,380.08-843.71-----
Net Margin--2,240.90-852.06-----
Shares Outstanding27.7627.5727.5613.8913.890.650.640.64
Market Capitalization548.06506.22164.76165.1810.4213.5516.0610.90

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments213.1934.7741.7947.8790.25137.04158.20209.92123.92
Short Term Receivables18.000.000.180.140.000.000.190.410.10
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets5.460.041.822.700.531.244.141.943.19
Total Current Assets236.6634.8043.7950.7190.79138.27162.53212.27127.22
Net Property, Plant & Equipment2.310.000.770.991.952.953.830.961.11
Total Investments and Advances0.110.000.000.000.000.000.000.000.00
Intangible Assets-0.00-0.000.000.000.000.000.00
Other Assets1.220.810.760.101.611.611.611.610.26
Total Assets240.2935.6245.3251.8194.35142.83167.97214.84128.58
Short Term Debt Incl. Current Port. of LT Debt0.430.000.740.921.000.900.800.000.00
Accounts Payable10.000.110.870.972.112.091.442.662.65
Other Current Liabilities25.649.515.236.998.729.448.716.105.53
Total Current Liabilities36.079.616.848.8811.8212.4310.958.768.17
Long Term Debt1.2141.480.070.000.921.922.820.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.260.000.610.71
Total Liabilities37.2851.106.908.8812.7414.6113.779.378.88
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value4.000.000.000.000.000.000.000.000.00
Common Equity199.01-15.4838.4142.9381.60128.22154.20205.46119.70
Total Shareholders Equity203.01-15.4838.4142.9381.60128.22154.20205.46119.70
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity203.01-15.4838.4142.9381.60128.22154.20205.46119.70
Total Liabilities & Stockholders Equity240.2935.6245.3251.8194.35142.83167.97214.84128.58
Book Value Per Share7.22-15.2059.6678.95155.99261.58354.75476.04348.38
Tangible Book Value Per Share7.22-15.2059.6678.95155.99261.58354.75476.04348.38
Full-Time Employees442635395254575040
Price to Book Ratio2.573.023.263.300.921.441.491.995.06
Return on Assets-122.48-44.15-75.98-63.89-53.48-32.84-30.25-28.11-38.93
Return on Equity-147.79-155.80-90.72-74.98-60.46-36.14-32.19-29.69-42.94
Return on Invested Capital-75.38-68.71-95.89-108.76-76.86-39.21-36.87-23.49-27.80
Quick Ratio6.563.626.415.717.6811.1314.8424.2215.56
Current Ratio6.563.626.415.717.6811.1314.8424.2215.56

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-165.12-153.94-17.87-36.90-46.69-63.43-51.03-57.89-48.27
Depreciation0.210.080.000.151.031.010.950.900.28
Other Funds (Non Cash)93.4395.702.144.433.866.096.906.224.59
Funds from Operations-71.49-58.16-15.73-32.32-41.80-56.32-43.17-50.78-43.41
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.18-13.379.46-2.56-4.66-1.173.93-1.210.08
Cash from Operating Activities-72.67-71.53-6.27-34.88-46.46-57.49-39.24-51.98-43.33
Capital Expenditures-80.94-72.920.00-0.02-0.08-0.01-0.07-0.14-0.13
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources1.770.000.000.000.000.000.000.000.00
Cash from Investing Activities-79.17-72.920.00-0.02-0.08-0.01-0.07-0.14-0.13
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-6.81-0.174.3228.824.1610.7218.140.41129.45
Repurchase of Common Pref Stock0.00-0.180.000.000.000.000.000.000.00
Sale of Common Pref Stock-6.810.014.3228.824.1610.7218.140.41129.45
Proceedsfrom Stock Options-6.810.000.0028.714.1610.7017.820.00128.43
Issuance or Reduction of Debt, Net-0.010.0036.720.000.000.000.000.000.00
Change in Long Term Debt0.000.0036.720.000.000.000.000.000.00
Issuance of Long Term Debt0.000.0036.720.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow177.61323.160.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities170.78322.9841.0328.824.1610.7218.140.41129.45
Net Change in Cash18.95178.5334.77-6.08-42.38-46.78-21.17-51.7285.99
Free Cash Flow-73.60-72.45-6.27-34.90-46.54-57.50-39.31-52.13-43.46
Preferred Dividends (Cash Flow)--0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments171.59189.16213.19133.26152.655.61
Short Term Receivables0.000.0018.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets7.416.405.461.301.580.38
Total Current Assets179.01195.56236.66134.56154.235.99
Net Property, Plant & Equipment2.152.302.312.351.800.00
Total Investments and Advances0.110.110.110.110.110.00
Intangible Assets-----0.00
Other Assets1.501.161.221.251.300.00
Total Assets182.76199.13240.29138.27157.435.99
Short Term Debt Incl. Current Port. of LT Debt0.470.450.430.420.210.00
Accounts Payable2.541.1910.002.561.650.10
Other Current Liabilities15.5212.5525.6417.3314.892.51
Total Current Liabilities18.5414.1936.0720.3016.752.62
Long Term Debt0.971.091.211.321.430.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities19.5015.2837.2821.6318.182.62
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value4.004.004.004.004.000.00
Common Equity159.25179.85199.01112.64135.253.38
Total Shareholders Equity163.25183.85203.01116.64139.253.38
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity163.25183.85203.01116.64139.253.38
Total Liabilities & Stockholders Equity182.76199.13240.29138.27157.435.99
Book Value Per Share5.746.527.228.119.745.23
Tangible Book Value Per Share5.746.527.228.119.745.23
Full-Time Employees--44-33-
Price to Book Ratio2.572.541.461,220.743.094.01
Return on Assets-97.08-158.03-112.29-72.70-45.29-146.71
Return on Equity-109.17-173.14-135.50-87.43-51.70-182.66
Return on Invested Capital-15.12-12.59-45.24-20.86-15.49-69.44
Quick Ratio9.6613.786.566.639.212.29
Current Ratio9.6613.786.566.639.212.29

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-24.84-23.28-92.40-24.61-34.59-2.34
Depreciation0.070.060.050.030.000.00
Other Funds (Non Cash)2.304.2184.842.088.370.41
Funds from Operations-22.48-19.01-7.50-22.50-26.22-1.94
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital3.0110.07-19.244.974.06-3.17
Cash from Operating Activities-19.46-8.94-26.74-17.52-22.16-5.11
Capital Expenditures-0.01-8.15-72.19-0.59-0.140.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources1.770.000.000.000.000.00
Cash from Investing Activities1.76-8.15-72.19-0.59-0.140.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)---0.000.000.00
Change in Capital Stock0.14-6.950.000.00-0.170.00
Repurchase of Common Pref Stock0.000.000.000.00-0.180.00
Sale of Common Pref Stock0.14-6.950.000.000.010.00
Proceedsfrom Stock Options0.14-6.950.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.00-0.010.010.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00178.86-1.25145.550.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.14-6.95178.86-1.27145.390.00
Net Change in Cash-17.57-24.0379.93-19.38123.09-5.11
Free Cash Flow-19.48-9.08-26.93-18.11-22.30-5.11

Revenue breakdown

Pharmaceutical Preparations2025: 10.84M
United States2025: 10.84M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3013.46%4.2M30.9M346.52K
2026-10-1514.30%4.4M30.9M371.30K
2026-09-3015.46%4.8M30.9M377.85K
2026-09-1511.02%3.4M30.9M344.55K
2026-08-3110.28%3.2M30.9M313.05K
2026-08-1410.42%3.2M30.9M335.75K
2026-07-3112.06%3.5M28.7M363.20K
2026-07-1513.10%3.7M28.6M341.49K
2026-06-3017.23%3.7M21.3M317.85K
2026-06-1515.45%3.3M21.7M274.22K
2026-05-2915.04%3.3M21.7M264.59K
2026-05-1513.39%2.9M21.7M248.89K
2026-04-3011.24%2.4M21.3M232.53K
2026-04-1510.46%2.2M21.3M221.14K
2026-03-3111.43%2.2M19.6M198.36K
2026-03-137.39%1.4M19.6M168.11K
2026-02-277.38%1.4M19.6M200.61K
2026-02-136.46%1.3M19.6M181.60K
2026-01-305.04%1.1M22.1M151.48K
2026-01-154.06%0.9M22.1M135.45K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call5.007.5011.500.0010.3610.000.000.986-0.0170.001
call7.505.009.000.007.0310.000.000.978-0.0170.001
call10.002.506.500.004.8980.000.000.823-0.2630.006
call12.500.004.900.004.4130.000.000.734-0.2370.008
call15.000.002.450.005.7760.000.000.638-0.2400.009
call17.500.004.900.003.7080.000.000.498-0.1930.009
call20.000.004.902.954.3798.000.000.459-0.2260.009
call22.500.004.902.054.9152.000.000.433-0.2520.009
call25.000.004.900.955.3611.000.000.415-0.2720.009
call30.000.004.900.009.2990.000.000.584-0.4390.009
call35.000.004.900.009.8480.000.000.573-0.4670.009
put5.000.004.900.003.6660.000.00-0.014-0.0170.001
put7.500.000.050.0510.58364.000.00-0.114-0.2460.004
put10.000.004.900.007.7840.000.00-0.177-0.2620.006
put12.500.004.901.005.55711.000.00-0.266-0.2360.008
put15.000.103.502.603.7204.000.00-0.414-0.1600.009
put17.501.505.501.704.0651.000.00-0.502-0.1910.009
put20.004.007.502.404.1911.000.00-0.541-0.2240.009
put22.506.5010.000.004.7280.000.00-0.567-0.2490.009
put25.009.0012.500.005.1750.000.00-0.585-0.2690.009
put30.0014.0017.500.005.8940.000.00-0.609-0.3000.009
put35.0019.0022.500.006.4600.000.00-0.625-0.3240.009

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-27SCHEDULE 13GSEC
2026-10-158-KCurrent report2026-10-15SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-18S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-16144Filing for proposed sale of securities under Rule 144.SEC
2026-09-16144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-07-31EFFECTEffectiveness filing by commission orderSEC
2026-07-30POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-07-30424B3SEC
2026-07-3010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-308-KCurrent report2026-07-30SEC
2026-07-20SCHEDULE 13D/ASEC
2026-07-204Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-158-KCurrent report2026-07-14SEC
2026-07-15424B5SEC
2026-07-148-KCurrent report2026-07-14SEC
2026-07-14424B5SEC
2026-07-10EFFECTEffectiveness filing by commission orderSEC
2026-07-01S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-234Statement of changes in beneficial ownership of securities2026-06-22SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0900285.50K9
2026-080000
2026-0712.38M100
2026-06001.23M7
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-1218.24M100
2025-110000

Institutional holders

Manager% owned
-

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.40%
iShares Russell 2000 ETF1.87%
Fidelity Growth Company Fund1.74%
Fidelity Small Cap Growth Fund1.40%
Fidelity Advisor Biotechnology Fund0.96%
Select Health Care Portfolio0.83%
iShares Russell 2000 Growth ETF0.72%
T. Rowe Price Health Sciences Fund, Inc.0.68%
Fidelity Small Cap Index Fund0.64%
Fidelity Small Cap Growth K6 Fund0.60%

OakChart. CBIO. Cached 15 minutes.